Vigil Neuroscience, Inc. (NASDAQ:VIGL – Get Free Report) saw a large drop in short interest during the month of December. As of December 15th, there was short interest totalling 681,400 shares, a drop of 18.4% from the November 30th total of 835,500 shares. Currently, 3.5% of the shares of the company are short sold. Based on an average daily volume of 190,300 shares, the short-interest ratio is currently 3.6 days.
Institutional Investors Weigh In On Vigil Neuroscience
Institutional investors and hedge funds have recently made changes to their positions in the business. Point72 Asset Management L.P. acquired a new position in Vigil Neuroscience during the second quarter worth about $5,940,000. abrdn plc acquired a new position in shares of Vigil Neuroscience during the 3rd quarter worth approximately $799,000. Ensign Peak Advisors Inc lifted its position in shares of Vigil Neuroscience by 72.8% in the second quarter. Ensign Peak Advisors Inc now owns 395,116 shares of the company’s stock valued at $1,580,000 after acquiring an additional 166,442 shares in the last quarter. Verition Fund Management LLC purchased a new position in Vigil Neuroscience in the 3rd quarter valued at about $442,000. Finally, Walleye Capital LLC boosted its stake in shares of Vigil Neuroscience by 334.4% during the 3rd quarter. Walleye Capital LLC now owns 119,792 shares of the company’s stock worth $407,000 after purchasing an additional 92,217 shares during the last quarter. 83.64% of the stock is currently owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
A number of equities research analysts have recently commented on VIGL shares. JMP Securities reiterated a “market outperform” rating and set a $22.00 target price on shares of Vigil Neuroscience in a research note on Tuesday, November 26th. Wedbush boosted their price target on shares of Vigil Neuroscience from $23.00 to $24.00 and gave the stock an “outperform” rating in a research note on Friday, November 8th. William Blair started coverage on shares of Vigil Neuroscience in a research report on Wednesday, December 4th. They issued an “outperform” rating for the company. Finally, HC Wainwright reiterated a “buy” rating and set a $17.00 target price on shares of Vigil Neuroscience in a research report on Friday, November 8th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Vigil Neuroscience has a consensus rating of “Buy” and a consensus target price of $19.75.
Vigil Neuroscience Price Performance
VIGL traded down $0.01 during trading on Friday, reaching $1.65. 202,764 shares of the stock were exchanged, compared to its average volume of 244,499. Vigil Neuroscience has a 1 year low of $1.54 and a 1 year high of $6.06. The company has a market capitalization of $67.45 million, a price-to-earnings ratio of -0.80 and a beta of 1.65. The business’s 50 day moving average price is $2.80 and its two-hundred day moving average price is $3.41.
About Vigil Neuroscience
Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.
Read More
- Five stocks we like better than Vigil Neuroscience
- Investing in Travel Stocks Benefits
- Power Up: Gaming Industry Expansion Fuels Stock Opportunities
- Technology Stocks Explained: Here’s What to Know About Tech
- These 3 Quirky ETFs May Be Strong Plays in 2025
- What is the Euro STOXX 50 Index?
- Buffett Takes the Bait; Berkshire Buys More Oxy in December
Receive News & Ratings for Vigil Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vigil Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.